News | Heart Failure | June 29, 2022

Changed Gene Expression After Heart Surgery Extends Cardiomyocyte Regeneration

Single-nucleus RNA-sequencing in a newborn pig model showed increased cell cycle activity and proliferation in cardiomyocytes, which helped remuscularize the left ventricle after experimental heart attack. 

University of Alabama at Birmingham researchers reported that surgery to remove the left ventricle apex of the heart of pigs, one day after birth, somehow extended the replication ability of heart muscle cells

Jianyi "Jay" Zhang, image courtesy of UAB 


June 29, 2022 — While lower vertebrates can repair their adult hearts after a heart attack, mammals — including humans — cannot. The ability to regenerate dead muscle tissue in mammalian hearts disappears just a few days after birth because the heart muscle cells, called cardiomyocytes, exit the cell cycle. 

After that, all growth of the heart comes from enlargement of existing cells, not from creation of new muscle cells. In an adult heart attack, heart failure results when the lost cardiomyocytes are replaced by fibrous scar tissue, instead of new muscle cells. This starts a vicious cycle of heart enlargement, loss of pumping function and eventual death. 

In 2020, University of Alabama at Birmingham researchers reported that surgery to remove the left ventricle apex of the heart of pigs, one day after birth, somehow extended the replication ability of heart muscle cells. In fact, after such surgery, pigs can completely recover from a heart attack four weeks after birth, without scarring or decline in heart function. 

To better understand the underlying gene expression changes in this extended regeneration window, UAB researchers now report nuclear RNA-sequencing of heart muscle cells, using this porcine model. From such knowledge, and much further research yet to come, clinicians may potentially learn how to regenerate adult heart cardiomyocytes after a heart attack. 

This study, led by Jianyi “Jay” Zhang, M.D., Ph.D., chair of the UAB Department of Biomedical Engineering, is published as a Circulation research letter. 

The researchers compared nuclei from heart tissue of five groups of pigs. Two groups were regeneration models that had left ventricle apical resections, or AR, at postnatal day one, or P1. One of those two groups then had ligation of the left anterior descending coronary artery four weeks after birth, or P28, to induce a myocardial infarction, or MI; this group is called ARP1MIP28. The other group, called ARP1, did not have ligation. 

Two non-regenerative controls did not have the P1 apical resection, but one of those did have the induced heart attack at P28. Those two groups were called Control and MIP28. 

Hearts were removed for single-nucleus RNA-sequencing at P30 through P56 for the ARP1MIP28 animals, and hearts from all other groups were explanted for sequencing on P1, P28 or P56. 

The fifth group were fetal hearts, or FH, at embryonic day 80. 

A total of 218,945 high-quality nuclei were captured, and a network biology clustering analysis identified all eight major heart cell types. Complete gene nucleus data were available for 94,844 cardiomyocytes. The cardiomyocytes were distributed among six clusters, named cardiomyocyte 1 through cardiomyocyte 6. 

Three clusters were almost entirely composed of cardiomyocytes from a single experimental group: cardiomyocyte 2 from control–P56, cardiomyocyte 3 from control–P1, and cardiomyocyte 6 from FH. 

The cardiomyocyte 4 and 5 clusters contained primarily ARP1MIP28–P35 cardiomyocytes. The cardiomyocyte 1 cluster included cardiomyocytes from all other animal groups and time points and a small number of ARP1MIP28–P35 cardiomyocytes, but few fetal or control–P56 cardiomyocytes. 

The cardiomyocyte 4 and 5 clusters that contained primarily ARP1MIP28–P35 cardiomyocytes showed increased cell cycle activity and proliferation, changes that helped remuscularize the left ventricle after experimental heart attack, without scarring. The researchers also found 506 genes that were positively correlated with the highly proliferative ARP1MIP28–P30 and ARP1MIP28–P35 cardiomyocytes; these genes participated in pathways that regulated heart development, cell proliferation and cardiomyocyte proliferation. 

“It will be interesting to examine these two distinct cell populations from the ARP1MIP28 injury in future studies,” Zhang said. “The findings are highly impactful because they show, for the first time, that the left ventricle can remuscularize the myocardial infarct beyond postnatal day seven, or P7, in large mammals. These observations provide a foundation for future investigations of the molecular mechanisms and signaling molecules that regulate the injury-induced preservation of cardiomyocyte cell cycle activity in newborn large mammals, and ultimately to remuscularize the heart muscle in patients suffering from heart attacks, thus preventing heart failure.” 

The study is titled “Single nucleus transcriptomics: Apical resection in newborn pigs extends the time window of cardiomyocyte proliferation and myocardial regeneration.” Co-authors with Zhang are Yuji Nakada, Yang Zhou, Eric Y. Zhang, Yuhua Wei, Meng Zhao, Wangping Chen, Jiacheng Sun and S. Naqi Raza, UAB Department of Biomedical Engineering; Thanh Nguyen and Jake Y. Chen, UAB Informatics Institute; Gregory P. Walcott, UAB Department of MedicineDivision of Cardiovascular Disease; and Wuming Gong, Erik Skie and Daniel J. Garry, School of Medicine, University of Minnesota, Minneapolis. 

Support came from National Institutes of Health grants HL114120, HL131017, HL149137 and HL134764. 

At UAB, Zhang holds the T. Michael and Gillian Goodrich Endowed Chair of Engineering Leadership. Biomedical Engineering is a joint department of the UAB Marnix E. Heersink School of Medicine and the UAB School of Engineering. The Informatics Institute and the Department of Medicine are part of the Heersink School of Medicine. 

For more information: https://www.uab.edu/home/ 

Related Heart Transplant News: 

Lab-grown Pig Heart Tissue Could Help Replace Live Animals in Heart Disease Research 

Pig Heart Transplant Patient Continues to Thrive 

First Human Receives a Pig Heart Transplant 

Transplanting Pig Hearts Into Humans One Step Closer 

FDA OKs Use New Version of Carmat Artificial Heart in U.S. Early Feasibility Study 

Carmat Artificial Heart Shows Promising Automatic Regulation of Blood Flow 

Heart in a Box Technology Expands Heart Transplant Window 

Abbott’s In-Development Fully Implantable Heart Pump System Earns FDA’s Breakthrough Device Designation 

FDA Clears SynCardia 50cc Temporary Total Artificial Heart as Bridge to Transplant 

Stephanie’s Heart: The Story of Baby Fae 

Hearts from donors who used illicit drugs or overdosed safe for transplant, cuts wait time 

National Trends in Heart Donor Utilization Rates: Are We Efficiently Transplanting More Hearts? 

Heart transplants from donors with hepatitis C may be safe and could help decrease organ shortage 

Find more cardiac surgery technology content 

Find more heart failure technology content 


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now